- Home
- EDRY vs COCH Comparison
EDRY vs COCH Comparison
Compare EDRY & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDRY | COCH |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | Greece | United States |
| Employees | N/A | 47 |
| Industry | Marine Transportation | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.6M | 49.7M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDRY | COCH |
|---|---|---|
| Price | $23.55 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 20.5K | ★ 125.1K |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.30 | $1.58 |
| Revenue Next Year | $10.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.64 | $0.36 |
| 52 Week High | $24.00 | $1.89 |
Technical Indicators
Market Signals| Indicator | EDRY | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 64.02 | 53.20 |
| Support Level | $11.73 | $0.63 |
| Resistance Level | N/A | $0.73 |
| Average True Range (ATR) | 1.32 | 0.04 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 88.96 | 56.07 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.